BioNTech & BMS Show Strong Lung Cancer Efficacy

Akeso Delivers Phase 3 Survival Win in NSCLC

Pfizer & Innovent Double Down on Multispecifics

FDA Approves HER2/HER3 Bispecific in Solid Tumours

Regeneron Expands $2B+ CytomX Bispecific Pact

Jazz & AbCellera Ink $4B Antibody Alliance

Chair’s Closing Remarks & End of Conference Day One

Chair’s Closing Remarks & End of Conference Day One

6:00 pm - Wednesday 16th September 2026